Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia - Wikidata - wikimedia - TriplyDB

Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia

Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia

http://www.wikidata.org/entity/Q35439947

about

Pneumocystis-Driven Inducible Bronchus-Associated Lymphoid Tissue Formation Requires Th2 and Th17 Immunity B Lymphocytes Are Required during the Early Priming of CD4+ T Cells for Clearance of Pneumocystis Infection in Mice.Immune reconstitution inflammatory syndrome associated with pulmonary pathogens A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study).Infectious complications of rituximab therapy in renal disease.Antibody-Independent Function of Human B Cells Contributes to Antifungal T Cell Responses.Transcriptomic Analysis Reveals Significant B Lymphocyte Suppression in Corticosteroid-Treated Hosts with Pneumocystis Pneumonia.A Novel CD4(+) T Cell-Dependent Murine Model of Pneumocystis-driven Asthma-like Pathology.New advances in understanding the host immune response to Pneumocystis.An Emerging Role of B Cell Immunity in Susceptibility to Pneumocystis Pneumonia.Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients.

P2860

Q33620933-1214CD55-2C5B-4761-A5C4-89CF5F14216A Q35816029-F0B5076E-D402-452E-9A3A-DCA5CBDF5D69 Q39065992-F27D06E9-38F7-469D-AB8F-6F7046B25087 Q39328482-4B76132E-0E9A-4666-9054-7B3AD9F488A0 Q40065728-FA1FF4E1-509A-47CE-A761-4E1E30943453 Q40302214-43696FBD-A260-4AD6-A512-5D20DEE13C8F Q40481810-1262D684-A260-48C4-8455-A7C2C0F79E6D Q40743958-25944F00-F92D-4DB7-B0FA-0BF5407B115C Q46516900-817DBD17-610D-4852-8312-F9E1E9FE90A4 Q52899594-A1498C76-1FD8-43E5-A951-C7B847A86BF2 Q55545384-312F0FE7-915A-4605-ADE9-83D03C375838

P2860

Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia

http://www.wikidata.org/entity/Q35439947

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia

@ast

Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia

@en

type

label

Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia

@ast

Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia

@en

prefLabel

Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia

@ast

Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia

@en

P1433

Q35439947-E1DD3F42-75F4-44FC-BA7D-154170A0647A

P1476

Q35439947-334D0D08-26CA-419C-BC2B-8423A0EC9107

P2093

Q35439947-9CC11E8C-A962-4556-AD0D-7D8CCEC7B461

Q35439947-AB4ADE77-2CBF-4F8E-9256-EEE91F182384

Q35439947-C7BF6C7F-1767-4418-9692-086FE9CACFD2

Q35439947-DB189DED-6664-474F-9483-80DE904BE3C8

P2860

Q35439947-0445A9AF-CEA9-4AC9-A434-11AE29EBCBF8

Q35439947-08223F7D-C663-4701-B7E4-0EEC4D411318

Q35439947-0BF0A667-CDB3-4D0B-BD60-BAC6AB86CF8A

Q35439947-1D2CC192-41F2-47DE-A515-03387D6081A1

Q35439947-1DB2CB8E-6E31-411D-AAB2-0793741D5A73

Q35439947-28151FB1-5AC4-489B-8EEB-234A20DB88A7

Q35439947-2C0BAE28-ED95-4AB8-9FF1-D91D268CBECB

Q35439947-2D7FF0A6-CAE6-42AA-9901-5026A4000DCB

Q35439947-304F6AF2-6B1E-4808-8806-CD247F0AB751

Q35439947-3EB5B15A-9018-48D5-802C-0E50B9E439BA

P304

Q35439947-6BBFF3F0-8101-483F-9207-ACFED265E973

P31

Q35439947-A447C49A-A9DB-4376-90AD-C0E34B3C9F4D

P356

Q35439947-3D93E140-EDFE-422C-AA82-4273871DDE1C

P407

Q35439947-18813772-9CC4-4D3B-B0E0-C47F4093588C

P433

Q35439947-128230E3-C88A-4971-9AD9-2B28E1067A2F

P478

Q35439947-10891CC8-8DAB-49F7-97E6-2205C628288E

P577

Q35439947-50F7DDD8-99D9-4207-8A22-D9E7FE02EE03

P698

Q35439947-73F6D6BA-4C2D-4D8E-8ABB-B868A663B965

P932

Q35439947-4D28E7A3-D569-4926-AE41-392C95B45274

P356

P1433

Infection and Immunity

P1476

Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia

@en

P2093

Jay K Kolls

http://www.w3.org/2001/XMLSchema#string

Kong Chen

http://www.w3.org/2001/XMLSchema#string

Taylor Eddens

http://www.w3.org/2001/XMLSchema#string

Waleed Elsegeiny

http://www.w3.org/2001/XMLSchema#string

P2860

CD20 deficiency in humans results in impaired T cell-independent antibody responses

Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population

The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease.

Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome.

CD8 T cells modulate CD4 T-cell and eosinophil-mediated pulmonary pathology in pneumocystis pneumonia in B-cell-deficient mice

Naturally acquired Pneumocystis carinii pneumonia in gene disruption mutant mice: roles of distinct T-cell populations in infection

Protection against Pneumocystis carinii pneumonia by antibodies generated from either T helper 1 or T helper 2 responses.

Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy.

Alveolar macrophage-mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the Dectin-1 beta-glucan receptor.

Pneumocystis pneumonia in patients treated with rituximab.

P304

2043-2052

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/IAI.03099-14

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

83

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25733518

http://www.w3.org/2001/XMLSchema#string

P932

4399075

http://www.w3.org/2001/XMLSchema#string